Increased MUC1 plus a larger quantity and complex size for MUC5AC in the peripheral airway lumen of long-term tobacco smokers
© 2020 The Author(s)..
There is little information on mucins versus potential regulatory factors in the peripheral airway lumen of long-term smokers with (LTS+) and without (LTS-) chronic obstructive pulmonary disease (COPD). We explored these matters in bronchoalveolar lavage (BAL) samples from two study materials, both including LTS+ and LTS- with a very similar historic exposure to tobacco smoke, and healthy non-smokers (HNSs; n=4-20/group). Utilizing slot blot and immunodetection of processed (filtered and centrifuged), as well as unprocessed BAL samples from one of the materials, we compared the quantity and fraction of large complexes of mucins. All LTS displayed an enhanced (median) level of MUC5AC compared with HNS. LTS- displayed a higher level of large MUC5AC complexes than HNS while LTS+ displayed a similar trend. In all LTS, total MUC5AC correlated with blood leukocytes, BAL neutrophil elastase and net gelatinase activity. Large mucin complexes accounted for most MUC5B, without clear group differences. In all LTS, total MUC5B correlated with total MUC5AC and local bacteria. In the same groups, large MUC5B complexes correlated with serum cotinine. MUC1 was increased and correlated with BAL leukocytes in all LTS whereas MUC2 was very low and without clear group differences. Thus, the main part of MUC5AC and MUC5B is present as large complexes in the peripheral airway lumen and historic as well as current exposure to tobacco smoke emerge as potential regulatory factors, regardless of COPD per se. Bacteria, leukocytes and proteinases also constitute potential regulatory factors, of interest for future therapeutic strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
Clinical science (London, England : 1979) - 134(2020), 10 vom: 29. Mai, Seite 1107-1125 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Padra, Médea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BAL |
|---|
| Anmerkungen: |
Date Completed 07.10.2020 Date Revised 07.10.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1042/CS20191085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309838894 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309838894 | ||
| 003 | DE-627 | ||
| 005 | 20231225134805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1042/CS20191085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309838894 | ||
| 035 | |a (NLM)32400877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Padra, Médea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased MUC1 plus a larger quantity and complex size for MUC5AC in the peripheral airway lumen of long-term tobacco smokers |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2020 | ||
| 500 | |a Date Revised 07.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Author(s). | ||
| 520 | |a There is little information on mucins versus potential regulatory factors in the peripheral airway lumen of long-term smokers with (LTS+) and without (LTS-) chronic obstructive pulmonary disease (COPD). We explored these matters in bronchoalveolar lavage (BAL) samples from two study materials, both including LTS+ and LTS- with a very similar historic exposure to tobacco smoke, and healthy non-smokers (HNSs; n=4-20/group). Utilizing slot blot and immunodetection of processed (filtered and centrifuged), as well as unprocessed BAL samples from one of the materials, we compared the quantity and fraction of large complexes of mucins. All LTS displayed an enhanced (median) level of MUC5AC compared with HNS. LTS- displayed a higher level of large MUC5AC complexes than HNS while LTS+ displayed a similar trend. In all LTS, total MUC5AC correlated with blood leukocytes, BAL neutrophil elastase and net gelatinase activity. Large mucin complexes accounted for most MUC5B, without clear group differences. In all LTS, total MUC5B correlated with total MUC5AC and local bacteria. In the same groups, large MUC5B complexes correlated with serum cotinine. MUC1 was increased and correlated with BAL leukocytes in all LTS whereas MUC2 was very low and without clear group differences. Thus, the main part of MUC5AC and MUC5B is present as large complexes in the peripheral airway lumen and historic as well as current exposure to tobacco smoke emerge as potential regulatory factors, regardless of COPD per se. Bacteria, leukocytes and proteinases also constitute potential regulatory factors, of interest for future therapeutic strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BAL | |
| 650 | 4 | |a leukocytes | |
| 650 | 4 | |a metalloproteases | |
| 650 | 4 | |a mucins | |
| 650 | 4 | |a neutrophils | |
| 650 | 4 | |a tobacco smoking | |
| 650 | 7 | |a Gases |2 NLM | |
| 650 | 7 | |a MUC1 protein, human |2 NLM | |
| 650 | 7 | |a Mucin 5AC |2 NLM | |
| 650 | 7 | |a Mucin-1 |2 NLM | |
| 650 | 7 | |a Mucin-2 |2 NLM | |
| 650 | 7 | |a Multiprotein Complexes |2 NLM | |
| 700 | 1 | |a Andersson, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Levänen, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Premaratne, Pushpa |e verfasserin |4 aut | |
| 700 | 1 | |a Asgeirsdottir, Helga |e verfasserin |4 aut | |
| 700 | 1 | |a Tengvall, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Christenson, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Stockfelt, Marit |e verfasserin |4 aut | |
| 700 | 1 | |a Bozinovski, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshihara, Shigemi |e verfasserin |4 aut | |
| 700 | 1 | |a Lantz, Ann-Sofie |e verfasserin |4 aut | |
| 700 | 1 | |a Palmberg, Lena |e verfasserin |4 aut | |
| 700 | 1 | |a Dahlén, Barbro |e verfasserin |4 aut | |
| 700 | 1 | |a Larsson, Kjell |e verfasserin |4 aut | |
| 700 | 1 | |a Qvarfordt, Ingemar |e verfasserin |4 aut | |
| 700 | 1 | |a Lindén, Sara K |e verfasserin |4 aut | |
| 700 | 1 | |a Lindén, Anders |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical science (London, England : 1979) |d 1980 |g 134(2020), 10 vom: 29. Mai, Seite 1107-1125 |w (DE-627)NLM000401536 |x 1470-8736 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2020 |g number:10 |g day:29 |g month:05 |g pages:1107-1125 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1042/CS20191085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2020 |e 10 |b 29 |c 05 |h 1107-1125 | ||